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Re-Examining the 1- Versus 2-Stent Argument*Aaron V. Kaplan, MDT he study by Lee et al. (1) in this issue of JACC:Cardiovascular Interventions provides impor-tant insights into the evolving treatment of
coronary bifurcation lesions, as well as the utility of
well-designed clinical registries. Before the introduc-
tion of stents, “plain old balloon angioplasty” was
limited by procedural unpredictability (abrupt
closure) and poor durability (restenosis). The intro-
duction of bare-metal stents was transformative,
providing procedure reliability with virtual elimina-
tion of emergent coronary artery bypass surgery.SEE PAGE 1318The introduction of drug-eluting stents brought dura-
bility to the procedure, reducing clinical restenosis to
acceptable rates (2,3). Technological advances, along
with reﬁnement of technique, have led to the uniform
adoption of a stenting strategy for almost all lesions
(4). The only major lesion subset in which a stent-all
strategy has not become the standard is the treatment
of side branches involved in bifurcation lesions. The
currently accepted strategy for “true” bifurcation
lesions is, in fact, to avoid the use of a second stent.
Lee et al. (1) provide data that challenge the current
dogma.
Coronary bifurcation lesions continue to challenge
the interventional cardiologist. The wide pathoana-
tomic variation makes these lesions difﬁcult to treat
and study. Currently available stents have been
designed for treatment of straight (nonbifurcation)
lesions. Using these stents to treat bifurcation lesions*Editorials published in JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Interventions or the American College of Cardiology.
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stent.forces the interventionist to adopt creative solutions,
e.g., the crush, mini-crush, culotte, double barrel,
“V,” “T,” and so on, all of which are complex and fail
to provide the same predictability and durability we
now have with the treatment of straight lesions (5).
This has led many, including myself, to develop
stents designed speciﬁcally for bifurcation lesions.
The current 1-stent strategy zeitgeist is based on a
series of randomized controlled trials (RCTs), most
notably the BBC ONE (British Bifurcation Coronary
Study) and NORDIC ONE (Nordic Bifurcation Study),
which failed to show beneﬁt of a 2-stent strategy
(6,7). Although the role of randomized trials is central
to the formation of our treatment strategies, there are
many factors that may limit the generalizability of a
speciﬁc RCT to current practice. These include the
highly selected study population, the technology be-
ing used, and the technique used. The markedly
variable nature of bifurcation anatomy and distribu-
tion of angiographically apparent disease, as well as
evolving stent technology and techniques, have made
the published data particularly difﬁcult to generalize
to “real world” usage and underlines the importance
of registries in placing RCTs into appropriate context.
The NORDIC ONE (September 2004 to May 2005)
and BBC ONE (December 2004 to December 2007)
studies were performed early in the drug-eluting
stent era and capture the technology and technique
of that time. These studies used ﬁrst-generation stent
technology (NORDIC ONE: Cypher Select sirolimus-
eluting stent [Cordis Corporation, Bridgewater, New
Jersey]; and BBC ONE: Taxus paclitaxel-eluting stent
[Boston Scientiﬁc, Natick, Massachusetts]). Contem-
porary stent technology has improved strut and
polymer drug delivery systems. A measure of this
change is the reduction in strut diameter: for
example, the ﬁrst-generation Cypher strut had an
overall thickness of 153 mM (metal 140 mM, polymer
12.6 mM), whereas the second-generation Xience
V/Promus (Abbott Vascular, Santa Clara, California)
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1333has an overall strut thickness of 88.6 mM (81 mM
metal, 7.6 mM polymer) (8). The 2-stent techniques
utilized in these studies favored the crush technique
(NORDIC ONE: crush 50%, culotte 21% and other
[primarily ‘T”] 29%; BBC ONE: crush 68.1%, culotte
30.2%, other 1.6%) differ from current 2-stent prac-
tice, which favors the “T” stent technique. Further-
more, current technique emphasizes ﬁnal kissing
inﬂations with “noncompliant” balloons as well as
post-optimization technique (1).
Lee et al. (1) present a patient-level pooled analysis
from 3 Korean Registries: the COBIS (Coronary Bifur-
cation Stenting Registry) dedicated bifurcation regis-
try, which is combined with appropriate patients
enrolled in the EXCELLENT (Efﬁcacy of Xience/Pro-
mus Versus Cypher to Reduce Late Loss After Stenting)
(everolimus-eluting stents: Xience V/Promus) and
Resolute-Korea, “all comers” registries. These 3 reg-
istries together provide a well-characterized large
study population (n ¼ 3,162). Utilizing sophisticated
statistical tools, the authors compared outcomes of
patients with bifurcation lesions treated with 1 or 2
stents utilizing ﬁrst-generation stents (Cypher and
Taxus) versus those treated with second-generation
stents (Xience V/Promus, Endeavor-Resolute [Med-
tronic, Minneapolis, Minnesota]) stents. Signiﬁcant
outcome differences were observed between the ﬁrst-
and second-generation groups. In the ﬁrst-generation
group, the 2-stent group had a greater target lesion
failure rate with increased cardiac death, spontaneous
myocardial infarction, target vessel revascularization,
and stent thrombosis (deﬁnite and probable). In the
second-generation group, these differences were not
observed.
The Korean Group reports interesting changes
in procedural technique in the 2-stent strategy in-
cluding a decrease in crush stenting (from 48.0% in
ﬁrst-generation to 35.2% in second-generation cases)
and an increase in T-stenting (from 36.4% in ﬁrst-
generation to 52.9% in second-generation cases).
There was an overall increase in the use of non-
compliant balloons during the ﬁnal inﬂation in both
the main branch (23.0% to 49.5%) and side branch
(10.0% to 37.1%). Also of interest was the frequency
with which a second stent was used in the provisionalarm (increased from 10.8% to 18.5%, rates derived
from the provisional 2-stent rates [see Table 2 of Lee
et al. (1)]). Both rates are higher than reported in the
NORDIC ONE (4.3%) or BBC ONE (2.8%) trial. This
difference likely reﬂects the protocol recommenda-
tion as well as differences between the BBC ONE and
Nordic ONE study populations and “real world”
lesions encountered in the unselected population
studied by the Korean investigators. It is important to
note that despite changes in technique, intrapro-
cedural side branch closure remained high in both the
ﬁrst- (6.2%) and second-generation (7.3%) cohorts.
Lee et al. (1), show how interventional technique is
continuing to evolve and suggest that our ability to
treat bifurcation lesions is improving. The emphasis
of RCTs in the published data pushes the interven-
tionist to adopt 1 approach (e.g., 1- vs. 2-stent strat-
egy) for all lesions and not just those matching the
highly focused lesion subset studied in a single study.
This forces a false choice, which ignores the wide
pathoanatomic variation observed among bifurcation
lesions. It seems more appropriate to individualize
one’s approach focused on anatomic variables that
make a lesion appropriate for 1 of a number of 1- or 2-
stent strategies. Data from Lee et al. (1) should give us
further comfort that utilization of a 2-stent strategy
with current technology and technique does not carry
long-term penalties.
Bifurcation lesions, with their wide pathoanatomic
variation, are particularly difﬁcult to study in RCTs,
which by their nature, examine only a narrow portion
of the lesion spectrum (e.g., limiting recruitment to
patients with discrete side branch disease), where
there is perceived equipoise between strategies
among investigators. The difﬁculty and expense
associated with RCTs will severely limit the number
of future studies, requiring us to rely increasingly on
registry data like those presented by Lee et al. (1) to
guide our treatment decisions.
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